Previously treated metastatic TNBC and HR positive HER2 negative breast cancer, germline BRCA 1/2 mutatedolaparib vs. investigator choice of therapy (capecitabine, vinorelbine, eribulin). This evidence concerns the gene ERBB2 and breast carcinoma.